Stifel Financial Corp Raises Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Stifel Financial Corp raised its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 140.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,347 shares of the company's stock after purchasing an additional 27,048 shares during the period. Stifel Financial Corp owned 0.09% of Prestige Consumer Healthcare worth $3,619,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Kestra Investment Management LLC purchased a new position in Prestige Consumer Healthcare in the 4th quarter valued at about $27,000. CIBC Private Wealth Group LLC boosted its stake in shares of Prestige Consumer Healthcare by 48.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after acquiring an additional 152 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter worth approximately $40,000. GAMMA Investing LLC raised its position in shares of Prestige Consumer Healthcare by 18.9% in the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock valued at $108,000 after buying an additional 220 shares during the last quarter. Finally, Huntington National Bank boosted its holdings in shares of Prestige Consumer Healthcare by 133.2% during the 4th quarter. Huntington National Bank now owns 1,481 shares of the company's stock worth $116,000 after purchasing an additional 846 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE:PBH traded up $0.29 during trading on Wednesday, reaching $81.32. The company had a trading volume of 71,819 shares, compared to its average volume of 291,129. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The stock's fifty day moving average price is $83.15 and its 200 day moving average price is $81.11. Prestige Consumer Healthcare Inc. has a fifty-two week low of $62.35 and a fifty-two week high of $90.04. The firm has a market capitalization of $4.03 billion, a price-to-earnings ratio of 19.02, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analysts Set New Price Targets

PBH has been the subject of several analyst reports. Royal Bank of Canada upped their target price on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a report on Friday, March 21st. DA Davidson upped their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday, February 7th. Oppenheimer lifted their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Finally, Canaccord Genuity Group lifted their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.